Tiffany Patrice Hogan, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Language Development Disorders | 15 | 2024 | 193 | 6.670 |
Why?
|
Dyslexia | 22 | 2023 | 215 | 5.950 |
Why?
|
Phonetics | 18 | 2023 | 204 | 3.180 |
Why?
|
Reading | 13 | 2023 | 543 | 3.030 |
Why?
|
Language Tests | 14 | 2024 | 193 | 3.000 |
Why?
|
Communication Disorders | 3 | 2023 | 50 | 2.450 |
Why?
|
Child Language | 11 | 2024 | 62 | 2.070 |
Why?
|
Speech-Language Pathology | 3 | 2022 | 28 | 2.030 |
Why?
|
Language Disorders | 5 | 2023 | 140 | 1.420 |
Why?
|
Speech | 11 | 2023 | 558 | 1.390 |
Why?
|
Vocabulary | 11 | 2023 | 167 | 1.330 |
Why?
|
Comprehension | 3 | 2023 | 641 | 1.280 |
Why?
|
Speech Perception | 4 | 2018 | 512 | 1.210 |
Why?
|
Memory, Short-Term | 8 | 2022 | 1010 | 1.150 |
Why?
|
Schools | 7 | 2023 | 1496 | 1.030 |
Why?
|
Language Development | 7 | 2022 | 184 | 0.970 |
Why?
|
Verbal Learning | 6 | 2022 | 465 | 0.720 |
Why?
|
Apraxias | 2 | 2018 | 58 | 0.710 |
Why?
|
Speech Disorders | 2 | 2018 | 180 | 0.680 |
Why?
|
Language Therapy | 5 | 2019 | 25 | 0.670 |
Why?
|
Child | 44 | 2024 | 80891 | 0.570 |
Why?
|
Neisseria gonorrhoeae | 5 | 2021 | 249 | 0.550 |
Why?
|
Awareness | 4 | 2020 | 653 | 0.540 |
Why?
|
Memory Disorders | 3 | 2019 | 1203 | 0.520 |
Why?
|
Professional Role | 1 | 2018 | 316 | 0.510 |
Why?
|
Psycholinguistics | 2 | 2016 | 81 | 0.450 |
Why?
|
Gonorrhea | 5 | 2021 | 355 | 0.450 |
Why?
|
Students | 1 | 2023 | 1744 | 0.420 |
Why?
|
Caregivers | 1 | 2024 | 2303 | 0.390 |
Why?
|
Multilingualism | 3 | 2019 | 88 | 0.380 |
Why?
|
Language | 4 | 2023 | 1558 | 0.310 |
Why?
|
Child, Preschool | 17 | 2024 | 42650 | 0.310 |
Why?
|
Drug Resistance, Bacterial | 5 | 2021 | 1063 | 0.290 |
Why?
|
Mass Screening | 2 | 2024 | 5451 | 0.290 |
Why?
|
Learning | 4 | 2023 | 1761 | 0.270 |
Why?
|
Humans | 59 | 2024 | 768393 | 0.250 |
Why?
|
Educational Status | 2 | 2023 | 2518 | 0.250 |
Why?
|
Neuropsychological Tests | 2 | 2019 | 7145 | 0.240 |
Why?
|
Pandemics | 2 | 2022 | 8753 | 0.240 |
Why?
|
Semantics | 6 | 2022 | 618 | 0.230 |
Why?
|
Linguistics | 4 | 2021 | 110 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3118 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3241 | 0.200 |
Why?
|
Perception | 1 | 2009 | 1205 | 0.200 |
Why?
|
Speech Production Measurement | 2 | 2018 | 99 | 0.190 |
Why?
|
Residence Characteristics | 1 | 2010 | 2122 | 0.170 |
Why?
|
Gentamicins | 1 | 2021 | 244 | 0.170 |
Why?
|
Longitudinal Studies | 9 | 2023 | 14784 | 0.170 |
Why?
|
Azithromycin | 2 | 2018 | 200 | 0.170 |
Why?
|
Meningococcal Infections | 1 | 2020 | 78 | 0.170 |
Why?
|
Neisseria meningitidis | 1 | 2020 | 111 | 0.170 |
Why?
|
Reproducibility of Results | 5 | 2024 | 20224 | 0.170 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2015 | 3743 | 0.170 |
Why?
|
Anti-Bacterial Agents | 5 | 2021 | 7463 | 0.160 |
Why?
|
Peer Group | 1 | 2024 | 698 | 0.160 |
Why?
|
Speech Therapy | 1 | 2018 | 58 | 0.160 |
Why?
|
Male | 27 | 2024 | 364902 | 0.140 |
Why?
|
Evidence-Based Practice | 1 | 2022 | 500 | 0.140 |
Why?
|
Space Perception | 2 | 2017 | 467 | 0.140 |
Why?
|
Female | 28 | 2024 | 397089 | 0.140 |
Why?
|
Association Learning | 1 | 2018 | 223 | 0.140 |
Why?
|
Visual Perception | 3 | 2017 | 1406 | 0.130 |
Why?
|
Jaw | 1 | 2016 | 95 | 0.130 |
Why?
|
Writing | 1 | 2018 | 200 | 0.130 |
Why?
|
Task Performance and Analysis | 2 | 2018 | 771 | 0.130 |
Why?
|
Predictive Value of Tests | 2 | 2024 | 15455 | 0.120 |
Why?
|
Early Diagnosis | 2 | 2010 | 1195 | 0.120 |
Why?
|
Lip | 1 | 2016 | 198 | 0.120 |
Why?
|
Feedback, Sensory | 1 | 2015 | 58 | 0.120 |
Why?
|
Laboratory Proficiency Testing | 1 | 2013 | 20 | 0.110 |
Why?
|
Communication Aids for Disabled | 1 | 2014 | 56 | 0.110 |
Why?
|
Executive Function | 2 | 2021 | 1405 | 0.110 |
Why?
|
Qualitative Research | 1 | 2024 | 3131 | 0.110 |
Why?
|
Cluster Analysis | 1 | 2020 | 2728 | 0.100 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2017 | 710 | 0.100 |
Why?
|
Microbial Sensitivity Tests | 5 | 2021 | 1961 | 0.100 |
Why?
|
Ceftizoxime | 1 | 2011 | 5 | 0.090 |
Why?
|
Ceftriaxone | 3 | 2020 | 175 | 0.090 |
Why?
|
Computers | 1 | 2014 | 592 | 0.090 |
Why?
|
Logistic Models | 2 | 2020 | 13323 | 0.090 |
Why?
|
Iowa | 1 | 2010 | 101 | 0.090 |
Why?
|
New South Wales | 2 | 2021 | 69 | 0.080 |
Why?
|
Cephalosporins | 1 | 2011 | 200 | 0.080 |
Why?
|
Population Density | 1 | 2010 | 193 | 0.080 |
Why?
|
Statistics as Topic | 1 | 2016 | 2363 | 0.080 |
Why?
|
Curriculum | 1 | 2023 | 3776 | 0.080 |
Why?
|
Cerebral Palsy | 1 | 2014 | 479 | 0.080 |
Why?
|
Cognition | 3 | 2017 | 7075 | 0.080 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2013 | 620 | 0.080 |
Why?
|
Disease Outbreaks | 1 | 2018 | 1762 | 0.080 |
Why?
|
Bayes Theorem | 3 | 2022 | 2353 | 0.070 |
Why?
|
Risk Factors | 4 | 2024 | 74962 | 0.070 |
Why?
|
Ciprofloxacin | 2 | 2020 | 313 | 0.070 |
Why?
|
Linear Models | 1 | 2016 | 5878 | 0.070 |
Why?
|
Cultural Diversity | 1 | 2010 | 373 | 0.070 |
Why?
|
Intelligence | 3 | 2017 | 929 | 0.070 |
Why?
|
Penicillins | 2 | 2020 | 406 | 0.060 |
Why?
|
Parents | 1 | 2019 | 3596 | 0.060 |
Why?
|
Campylobacter jejuni | 1 | 2004 | 24 | 0.060 |
Why?
|
Acoustic Stimulation | 1 | 2009 | 1253 | 0.060 |
Why?
|
Campylobacter Infections | 1 | 2004 | 32 | 0.060 |
Why?
|
DNA Gyrase | 1 | 2004 | 86 | 0.050 |
Why?
|
Australia | 2 | 2020 | 1265 | 0.050 |
Why?
|
Quality Assurance, Health Care | 1 | 2013 | 2181 | 0.050 |
Why?
|
Analysis of Variance | 3 | 2019 | 6241 | 0.050 |
Why?
|
Risk Assessment | 1 | 2024 | 24318 | 0.050 |
Why?
|
Adult | 6 | 2024 | 223640 | 0.050 |
Why?
|
Mental Recall | 2 | 2019 | 1226 | 0.050 |
Why?
|
Intelligence Tests | 2 | 2017 | 505 | 0.050 |
Why?
|
Quinolones | 1 | 2004 | 382 | 0.040 |
Why?
|
Models, Educational | 1 | 2003 | 375 | 0.040 |
Why?
|
Adolescent | 5 | 2018 | 89184 | 0.040 |
Why?
|
Attention | 2 | 2021 | 2425 | 0.040 |
Why?
|
RNA, Ribosomal, 23S | 1 | 2018 | 54 | 0.040 |
Why?
|
Northern Territory | 1 | 2017 | 5 | 0.040 |
Why?
|
England | 1 | 2019 | 532 | 0.040 |
Why?
|
Spain | 1 | 2019 | 492 | 0.040 |
Why?
|
Infant | 3 | 2020 | 36510 | 0.040 |
Why?
|
Games, Experimental | 1 | 2017 | 32 | 0.040 |
Why?
|
Multilocus Sequence Typing | 1 | 2017 | 102 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2015 | 15939 | 0.030 |
Why?
|
Anti-Infective Agents | 1 | 2004 | 985 | 0.030 |
Why?
|
Amoxicillin | 1 | 2017 | 182 | 0.030 |
Why?
|
Heterosexuality | 1 | 2018 | 309 | 0.030 |
Why?
|
Molecular Epidemiology | 1 | 2017 | 473 | 0.030 |
Why?
|
Video Games | 1 | 2017 | 202 | 0.030 |
Why?
|
Age Distribution | 1 | 2020 | 2877 | 0.030 |
Why?
|
Speech Acoustics | 1 | 2015 | 155 | 0.030 |
Why?
|
Speech Intelligibility | 1 | 2014 | 80 | 0.030 |
Why?
|
Young Adult | 2 | 2018 | 60049 | 0.030 |
Why?
|
Point Mutation | 1 | 2018 | 1594 | 0.030 |
Why?
|
Photic Stimulation | 1 | 2019 | 2004 | 0.030 |
Why?
|
Contingent Negative Variation | 1 | 2012 | 36 | 0.030 |
Why?
|
Cefixime | 1 | 2011 | 13 | 0.020 |
Why?
|
Middle Aged | 4 | 2020 | 223491 | 0.020 |
Why?
|
Comorbidity | 2 | 2017 | 10588 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2017 | 14737 | 0.020 |
Why?
|
Penicillin-Binding Proteins | 1 | 2011 | 152 | 0.020 |
Why?
|
Homosexuality, Male | 1 | 2018 | 1345 | 0.020 |
Why?
|
Population Surveillance | 1 | 2020 | 2598 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2017 | 22296 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2018 | 2986 | 0.020 |
Why?
|
Sex Factors | 1 | 2021 | 10654 | 0.020 |
Why?
|
Articulation Disorders | 1 | 2005 | 13 | 0.020 |
Why?
|
Bacterial Proteins | 1 | 2018 | 3838 | 0.010 |
Why?
|
Mental Processes | 1 | 2005 | 247 | 0.010 |
Why?
|
Genotype | 1 | 2018 | 13042 | 0.010 |
Why?
|
Decision Making | 1 | 2017 | 3953 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2011 | 4775 | 0.010 |
Why?
|
Alleles | 1 | 2011 | 6892 | 0.010 |
Why?
|
Communication | 1 | 2014 | 3912 | 0.010 |
Why?
|
Mutation | 1 | 2004 | 30228 | 0.010 |
Why?
|
DNA, Bacterial | 1 | 2004 | 1479 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2011 | 10776 | 0.010 |
Why?
|
Auditory Perception | 1 | 2003 | 588 | 0.010 |
Why?
|
Educational Measurement | 1 | 2003 | 1256 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 2004 | 4120 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2004 | 6085 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2005 | 13020 | 0.010 |
Why?
|
Prognosis | 1 | 2003 | 30022 | 0.000 |
Why?
|